This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
EPD Growth in Emerging Market Supports Abbott Stock Amid Macro Woes
by Zacks Equity Research
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
ABTNegative Net Change BSXNo Net Change MASINegative Net Change HIMSNegative Net Change
medical medical-devices
WST Stock Rises on Q1 Earnings Beat, EPS View Up on Tariff & FX Benefit
by Zacks Equity Research
West Pharmaceutical's first-quarter top line continues to benefit from revenue growth in its Proprietary Products segment.
MASINegative Net Change FMSNegative Net Change WSTNegative Net Change GKOSNegative Net Change
earnings medical medical-devices
Penumbra Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Expand
by Zacks Equity Research
PEN reports better-than-expected earnings and revenues in the first quarter of 2025.
ANGONegative Net Change MASINegative Net Change VEEVNegative Net Change PENNegative Net Change
earnings medical medical-devices
Should You Buy Regulus (RGLS) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
RGLSNo Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
EW Q1 Earnings & Revenues Beat, Stock Climbs, '25 Sales View Raised
by Zacks Equity Research
Edwards Lifesciences' first-quarter 2025 performance benefits from its differentiated portfolio of therapies to treat patients with structural heart disease.
ANGONegative Net Change EWPositive Net Change MASINegative Net Change VEEVNegative Net Change
earnings medical medical-devices
ISRG Stock Falls Despite Q1 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
ISRG's first-quarter results reflect a healthy demand for procedures on higher system utilization. However, tariffs lead to a decline in the gross margin outlook.
ISRGPositive Net Change MASINegative Net Change FMSNegative Net Change GKOSNegative Net Change
earnings medical medical-devices
BSX Q1 Earnings & Revenues Beat, Stock Up, 2025 View Raised
by Zacks Equity Research
Boston Scientific's first-quarter 2025 performance benefits from the strength of its product portfolio.
BSXNo Net Change ANGONegative Net Change MASINegative Net Change VEEVNegative Net Change
earnings medical medical-devices
Zacks Investment Ideas feature highlights: SPY, QQQ, MicroStrategy, GameStop and Semler Scientific
by Zacks Equity Research
SPY, QQQ, MicroStrategy, GameStop and Semler Scientific are part of the Zacks Investment Ideas article.
GMEPositive Net Change QQQPositive Net Change SPYNegative Net Change MSTRNegative Net Change SMLRNegative Net Change
computers consumer-discretionary etfs medical-devices
Tesla Q1 Misses on Top & Bottom Lines, Kicks Can on Guidance
by Mark Vickery
Tesla (TSLA) posted its sixth earnings miss in the past seven quarters, coming up -38.6% short.
ISRGPositive Net Change TSLAPositive Net Change
earnings electric-vehicles medical-devices
CVS Soars 53% in Q1: Time to Buy the Stock Ahead of Earnings Release?
by Urmimala Biswas
Caremark, CVS Health's PBM business, is expected to have continued to play a vital role in offsetting the rising cost of branded drugs during the first quarter.
CVSNegative Net Change HLFNegative Net Change WBANegative Net Change
earnings-estimates-revisions earnings-outlook earnings-preview earnings-report earnings-streak earnings-surprise healthcare medical medical-devices retail
Concentra Stock Slips Despite Deal to Acquire Pivot Onsite Innovations
by Zacks Equity Research
CON is set to acquire Pivot Onsite Innovations, expanding its onsite occupational health services and strengthening its national footprint in workforce health solutions.
ANGONegative Net Change MASINegative Net Change VEEVNegative Net Change CONNegative Net Change
medical medical-devices
BD Stock Down Despite Monitoring Platform Launch to Boost Patient Care
by Zacks Equity Research
BDX's AI-based advanced hemodynamic monitoring platform is likely to aid clinicians to address blood flow instability and pressure in critical situations and improve patient outcomes.
BDXNegative Net Change CORPositive Net Change LMATNegative Net Change VEEVNegative Net Change
medical medical-devices
Quest Diagnostics Q1 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
DGX delivers solid top-line growth in the first quarter of 2025.
ANGONegative Net Change DGXNegative Net Change MASINegative Net Change VEEVNegative Net Change
earnings medical medical-devices
Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside?
by Moumi Mondal
Both HOLX and Myriad Genetics are longstanding key players in the Molecular Diagnostics space. But which one is a better investment now?
HOLXNegative Net Change MYGNNegative Net Change
medical medical-devices
Will Segmental Performance Drive West Pharmaceutical's Q1 Earnings?
by Zacks Equity Research
West Pharmaceutical Services' first-quarter results are likely to reflect growth amid pharma stabilization, biologics rebound & contract manufacturing gains.
CAHPositive Net Change MMSINegative Net Change WSTNegative Net Change GMEDNegative Net Change
medical medical-devices
ECL Stock Gains Following 5% Trade Surcharge in the United States
by Zacks Equity Research
Ecolab announces a 5% U.S. trade surcharge to offset rising costs.
ECLNegative Net Change ANGONegative Net Change MASINegative Net Change VEEVNegative Net Change
medical medical-devices
Will Robust Exome and Genome Growth Boost WGS' Q1 Earnings Results?
by Zacks Equity Research
GeneDx is expected to have continued the strong 2024 momentum across all metrics in the first quarter of 2025.
FMSNegative Net Change VEEVNegative Net Change HIMSNegative Net Change WGSNegative Net Change
earnings medical medical-devices
ISRG Q1 Earnings Coming Up: Time to Buy, Sell or Hold the Stock?
by Zacks Equity Research
Intuitive Surgical's first-quarter results are likely to reflect solid performance in the company???s Instruments & Accessories segment. Improving margins buoy optimism.
MDTNegative Net Change ISRGPositive Net Change TMONegative Net Change
medical medical-devices
3 Medical Info Systems Stocks to Ride the AI Wave in Trump Tariff Era
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like VEEV, HIMS and BFLY are expected to gain from the Stargate Project and provide relief amid tariff tension.
VEEVNegative Net Change HIMSNegative Net Change BFLYNegative Net Change
artificial-intelligence blockchain cloud-computing medical medical-devices smart-health
Top Analyst Reports for Apple, Philip Morris & Sony
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Bank of Apple Inc. (AAPL), Philip Morris International Inc. (PM) and Sony Group Corp. (SONY), as well as a micro-cap stock Vaso Corp. (VASO).
AAPLNegative Net Change MMMNegative Net Change PMPositive Net Change TRVNegative Net Change VASOPositive Net Change SONYPositive Net Change EXEPositive Net Change
computers consumer-discretionary consumer-staples medical-devices
Should You Buy Boston Scientific Stock Ahead of Q1 Earnings?
by Urmimala Biswas
Banking on robust above-market growth across all business units, BSX is expected to have witnessed strong international momentum in the first quarter.
ABTNegative Net Change BSXNo Net Change MDTNegative Net Change
earnings-estimates-revisions earnings-outlook earnings-preview earnings-streak earnings-surprise healthcare medical medical-devices
Newmont Corporation (NEM) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
NEMNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
3 Undervalued Medical Device Stocks to Buy in 2025 Amid Tariff Woes
by Harshit Gupta
Here, we discuss three medical device stocks ,COR, HIMS and PBH, that offer cheap valuations, making them attractive bets amid tariff risks.
CORPositive Net Change PBHNegative Net Change HIMSNegative Net Change
medical medical-devices
Should You Continue to Hold Veracyte Stock in Your Portfolio?
by Zacks Equity Research
Strength in the Afirma and Decipher franchises continues to bode well for VCYT stock.
BSXNo Net Change MASINegative Net Change VCYTNegative Net Change HIMSNegative Net Change
medical medical-devices
4 Medical Product Stocks to Buy From a Challenging Industry
by Indrajit Bandyopadhyay
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from the favorable factors.
PODDPositive Net Change MGNXPositive Net Change CLRBPositive Net Change ALURPositive Net Change
medical medical-devices